|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400092891 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-26 08:10:34 |
|
注册时间: Date of Registration: |
2024-11-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
奥赛利定与舒芬太尼在妇科腹腔镜手术中预防性镇痛的效果比较 |
|
Public title: |
Comparison of oliceridine and sufentanil for prophylactic analgesia in gynecologic laparoscopic surgery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
奥赛利定与舒芬太尼在妇科腹腔镜手术中预防性镇痛的效果比较 |
|
Scientific title: |
Comparison of the efficacy of oliceridine versus sufentanil for preventive analgesia in gynecologic laparoscopic surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李林桂 |
研究负责人: |
徐翔 |
|
Applicant: |
Li Lingui |
Study leader: |
Xu Xiang |
|
申请注册联系人电话: Applicant telephone: |
+86 178 7538 9598 |
研究负责人电话:
Study leader's |
+86 134 2533 0422 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liligui33@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xuxiang716@sina.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省汕头市金平区学成路1号 |
研究负责人通讯地址: |
广东省汕头市金平区学成路1号 |
|
Applicant address: |
No.1 Xuecheng Road, Jinping District, Shantou, Guangdong, China |
Study leader's address: |
No.1 Xuecheng Road, Jinping District, Shantou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
汕头大学医学院附属肿瘤医院 |
||
|
Applicant's institution: |
Cancer Hospital of Shantou University Medical College |
||
|
研究负责人所在单位: |
汕头大学医学院附属肿瘤医院 |
||
|
Affiliation of the Leader: |
Cancer Hospital of Shantou University Medical College |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024007 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
汕头大学医学院附属肿瘤医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The medical ethics committee of the Shantou University Cancer Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-26 00:00:00 | ||
|
伦理委员会联系人: |
许晓莎 |
||
|
Contact Name of the ethic committee: |
Xu Xiaosha |
||
|
伦理委员会联系地址: |
广东省汕头市金平区饶平路7号 |
||
|
Contact Address of the ethic committee: |
No.7 Raoping Road, Jinping District, Shantou, Guangdong ,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 136 9202 2968 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
汕头大学医学院附属肿瘤医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Cancer Hospital of Shantou University Medical College |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广东省汕头市金平区学成路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1 Xuesheng Road, Jinping District, Shantou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广东省医学会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guangdong Medical Association |
||||||||||||||||||||||
|
研究疾病: |
妇科肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Gynecologic tumor |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过预防性使用奥赛利定和舒芬太尼在妇科腹腔镜手术进行镇痛后,评估患者术后疼痛程度,术中术后镇痛药物的使用量及术后并发症发生率,从而为奥赛利定的临床应用提供参考意见。 |
||||||||||||||||||||||
|
Objectives of Study: |
By preventively using Oliceridine and Sufentanil for analgesia in gynecological laparoscopic surgery, this study aims to assess the degree of postoperative pain in patients, the amount of analgesic medication used during and after surgery, and the incidence of postoperative complications, thereby providing reference opinions for the clinical application of Oliceridine. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.经医院伦理委员会批准,签署麻醉知情同意书和参与研究知情同意书,拟在气管插管全麻下行妇科腹腔镜手术的成年女性; 2.年龄18-65岁,ASA I~II级,体重指数BMI 18-28kg/m2 |
||||||||||||||||||||||
|
Inclusion criteria |
1.With the approval of the hospital's ethics committee, adult female patients who have signed the informed consent form for anesthesia and the informed consent form for participating in the study are planned to undergo gynecological laparoscopic surgery with endotracheal intubation under general anesthesia; 2.Age between 18 to 65 years old, classified as ASA I to II, with a body mass index (BMI) ranging from 18 to 28 kg/m2. |
||||||||||||||||||||||
|
排除标准: |
1.对研究药物过敏者 2.长期使用阿片类药物者 3.严重肝肾功能不全患者 4.存在胃肠道梗阻,有误吸风险者 5.术前24h内有恶心呕吐或使用预防性止呕药者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients allergic to the study medication. 2.Patients with long-term use of opioid drugs. 3.Patients with severe liver and kidney dysfunction. 4.Patients with gastrointestinal obstruction, at risk of aspiration. 5.Patients with nausea and vomiting within 24 hours preoperatively or those who have used prophylactic antiemetic drugs. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-01 00:00:00至 To 2026-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-12-01 00:00:00 至 To 2025-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由不参与手术麻醉的一名麻醉护士使用随机数字表法产生随机序列并进行分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A nurse anesthetist who does not participate in the surgery uses a random number table method to generate a random sequence and to group the subjects |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double blind |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表(Case Record Form, CRF)及二为电子采集和管理系统(Electronic Data Capture, EDC) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form(CRF) and Electronic Data Capture(EDC) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |